Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOther Non-Current AssetsPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rein Therapeutics (RNTX) Goodwill & Intangibles (2023 - 2025)

Rein Therapeutics has reported Goodwill & Intangibles over the past 3 years, most recently at $19.8 million for Q4 2025.

  • Quarterly Goodwill & Intangibles fell 59.14% to $19.8 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $19.8 million through Dec 2025, down 59.14% year-over-year, with the annual reading at $19.8 million for FY2025, 59.14% down from the prior year.
  • Goodwill & Intangibles was $19.8 million for Q4 2025 at Rein Therapeutics, down from $48.5 million in the prior quarter.
  • Over five years, Goodwill & Intangibles peaked at $85.5 million in Q4 2023 and troughed at $19.8 million in Q4 2025.
  • The 3-year median for Goodwill & Intangibles is $48.5 million (2024), against an average of $61.8 million.
  • Year-over-year, Goodwill & Intangibles crashed 43.26% in 2024 and then tumbled 59.14% in 2025.
  • A 3-year view of Goodwill & Intangibles shows it stood at $85.5 million in 2023, then crashed by 43.26% to $48.5 million in 2024, then tumbled by 59.14% to $19.8 million in 2025.
  • Per Business Quant, the three most recent readings for RNTX's Goodwill & Intangibles are $19.8 million (Q4 2025), $48.5 million (Q3 2025), and $48.5 million (Q2 2025).